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Abstracts / Biol Blood Marrow Transplant 19 (2013) S194eS210 S195Chimeric antigen receptors (CARs) are artiﬁcial mole-
cules that can be used to redirect T cell immune response
against antigens expressed on the surface of tumor cells.
Although promising, most current protocols expand engi-
neered T cells non-speciﬁcally using IL-2 and OKT3, which
decreases the frequency of transgenic populations over
time. Additionally, cell expansion using conventional cul-
tureware is complicated and labor intensive, which limits
the broader application of this therapy. With the grant
support from Production Assistance for Cell Therapy
(PACT), we assessed whether CAR T cell manufacture could
be optimized and streamlined by: (i) supplementing non-
speciﬁc stimuli (IL-2) with an artiﬁcial antigen presenting
cell (a-APC) engineered to express cognate antigen and co-
stimulatory molecules, and (ii) efﬁciently and rapidly
expanding cells in a simple and scalable gas permeable
culture device (G-Rex). As a proof of principle, we sought to
expand T cells engineered with a CAR targeting the prostate
cancer antigen, PSCA. We ﬁrst generated an a-APC cell line
by modifying K562 cells, which expressed a range of co-
stimulatory molecules including CD80, CD86, and 41BBL,
with a retroviral vector encoding the PSCA antigen. After
the co-culture of CAR-PSCA T cells with the irradiated
a-APC, we found that a-APCs co-expressing PSCA antigen,
CD80, and 41BBL were the most effective in inducing T cell
expansion, with a 1.9 fold increase in total cell numbers
when compared with CAR T cells expanded in the presence
of IL2 alone. We also saw an increase in the frequency of
transgenic CAR T cells which increased from 36.5% to 88.1%
after 10 days of culture. In contrast, the percentage of
transgenic T cells was sustained when cultured in the
presence of IL2 (36.5% on day 0 and 37.2% on day 10). Thus,
culture of CAR-T cells with antigen-expressing a-APCs not
only improves total cell output, but also enriches for
transgene-expressing. Next, to assess whether we could
scale up cell production we transferred the engineered
a-APCs and CAR-PSCA T cells (at a 2:1 ratio) into a static
GMP-compliant G-Rex with a surface area of 100cm2. In
these G-Rex devices, O2 and CO2 are exchanged across
a silicone membrane at the base, which allows for the
addition of an increased depth of medium above the cells.
These culture conditions have been shown to increase cell
output without increasing the number of cell doublings.
From an initial seeding density of 25E+06 CAR T cells, we
obtained a total of 2200-2500E+06 cells within 10 days of
culture. Thus, without any intervention we obtained a 93
fold increase in cell numbers using only 1 liter of T cell
culture media. We also observed an enrichment of trans-
genic T cells (from 33.2% to 81.7%, a 2.41.2 fold increase,
after 10 days of culture). Taken together the total T cell fold
expansion (93) and the enrichment for the transgene
(2.41.2), we calculate a 223.5111.6 fold expansion of CAR
T cells.164
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Background: Cytomegalovirus (CMV) continues to be an
important human pathogen in allogeneic hematopoietic
cell transplant (allo-HCT) recipients. Both CD4+ and CD8+
T cells are important for long-term control of the virus.
Identiﬁcation of CMV-speciﬁc T cell epitopes has primarily
focused on CD8+ T cell epitopes. Adoptive transfer of
CMV-speciﬁc CD4+ T cells has previously been associated
with prolonged protection from reactivation and CMV
disease.
Aims: To characterize the repertoire and restriction of CMV-
speciﬁc CD4+ T cell responses against immediate early
antigen 1 and 2 (IE1 and IE2) in 16 healthy, HLA-typed, CMV+
donors.
Methods: We performed IFN-g ELISPOT assays ex vivo on
PBMCs from CMV+ donors using 187 peptides (15 amino
acids long and overlapping 10 amino acids) spanning the
entire IE1 and IE2. These peptides were distributed into
individual microtiter wells, PBMCs from each donor were
added and incubated, and the resulting responses were
measured by IFN-g ELISPOT analysis. To validate the
peptide-speciﬁcity and to establish the phenotype of the
responding cells, peptides eliciting IFN-g release in the
ELISPOT analysis were subsequently used to stimulate
PBMCs in vitro for 12-14 days followed by ﬂow cytometric
intracellular cytokine secretion assay. For the identiﬁed
CD4+ T cell responses, peptide-MHC class II (MHCII) afﬁnity
measurements were used to suggest the most likely
restricting element(s) among the donors MHCII molecules.
To validate MHCII restriction element(s), MHCII tetramers
(TMR) were generated and used to label in vitro stimulated
PBMCs.
Results: We have identiﬁed 27 CD4+ T cell epitopes in IE1
and IE2; 19 of these are novel. Several CD4+ T cell epitopes
appeared to be immunodominant. Thus, one DRB1*0101-
restricted IE2 epitope was recognized by 5/5 DRB1*0101-
positive donors, two DRB1*0301-restricted epitopes, one in
IE2 and one in IE1, were recognized by 4/4 and 4/4
DRB1*0301-positive donors, respectively, and one
DRB5*0101-restricted IE1 epitope was recognized by 4/4
DRB5*0101-positive donors. Additional epitopes appear to be
immunodominant by functional analysis, but have not yet
been validated with MHCII TMRs.
Conclusions: We have found multiple novel CD4+ epitopes
in CMV IE1 and IE2 of which several have been validatedwith
MHCII TMRs. These epitopes could be used to explore the
reconstitution of CMV-speciﬁc CD4+ T cells following allo-
HCT, and they could represent promising candidates for
adoptive CD4+ T cell transfer.166
Evaluating Donor Lymphocyte Infusions (DLI) for the
Treatment of Falling Chimerism, Minimal Residual
Disease and Relapse After Pediatric Hematopoietic Stem
Cell Transplantation (HSCT)
Javier Amin El-Bietar 1, Caridad Martinez 1,
Catherine M. Bollard 1, Swati Naik 1, Kathryn Leung 1,
Stephen Gottschalk 1, Nabil Ahmed 2, Carl Allen 1,
Helen E. Heslop 1, Malcolm K. Brenner 1, Robert A. Krance 1.
1 Center for Cell and Gene Therapy, Baylor College of Medicine,
Texas Children's Hospital, Houston, TX; 2 Center for Cell and
Gene Therapy-Dept of Pediatrics Hem/Onc, Baylor College of
Medicine, Houston, TX
Abstracts / Biol Blood Marrow Transplant 19 (2013) S194eS210S196We conducted an eleven-year retrospective review
(2001-2012) of 65 HSCT patients with myeloid malignan-
cies (n¼ 32), lymphoid malignancies (n¼27) or CML (n¼6)
who received DLI post-transplant to treat mixed chimerism
(MC, n¼15), minimal residual disease (MRD, n¼15) or
relapsed disease (RD, n¼35). Patients had received trans-
plants from related (n¼20) including haploidentical (n¼26),
unrelated (n¼35) or cord blood (n¼1) donors. Forty-two
patients received total body irradiation (TBI) and cyclo-
phosphamide-based conditioning while 16 received
busulfan and cyclophosphamide-based regimens. Twenty-
seven patients received conditioning with other chemo-
therapies  TBI. MC was deﬁned as evidence of recipient
cells on whole blood or bone marrow analysis using ﬂuo-
rescence in-situ hybridization (FISH) or short tandem
repeats. Nine of the 15 MC patients who received DLI did so
after the discontinuation (median of 35 days, range 1-217)
of graft versus host disease (GvHD) prophylaxis, while the 6
remaining DLI recipients had not been on prophylactic
therapy. MRD was deﬁned as the detection of a clone 
0.01% using polymerase chain reaction or FISH. Relapse was
deﬁned as any patient with a  5% blast population
detected in peripheral blood and conﬁrmed by microscopic
or ﬂow cytometric analysis. As a group, 26/65 patients are
alive after receiving DLI with a median follow-up of 24
months (range 3-102). Of patients with MC, 9/15 remained
in remission for a median of 22 months (range 3-85) with
7/15 experiencing Grade II-IV aGvHD. Of patients with
MRD, 12/15 remained in remission for a median of 77
months (range 5-102) with 5/15 experiencing grade II-IV
aGvHD. Eight of these 12 surviving patients were Phila-
delphia chromosome-positive. Of patients with RD, 5/36
remain alive with 3/5 in remission for a median of 43
months (range 4-63). 11/31 patients who expired experi-
enced Grade II-IV aGvHD. Hence, DLI may beneﬁt pediatric
myeloid and lymphoid malignancy patients post-HSCT with
MC and MRD (especially those with Philadelphia chromo-
some-positive leukemia). However, DLIs produced remis-
sion in only 3/36 patients with RD and the associated risk
of signiﬁcant GvHD likely worsens quality of remaining life
in the non-responders.167
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Interest in ex vivo hematopoietic stem and progenitor cell
(HSPC) expansion has increased in recent years due to the
growing importance of these cells in the treatment of
a variety of both malignant and non-malignant diseases. Ex
vivo expansion of cord blood-derived cells has been partic-
ularly investigated because cord is a valuable and readily
available source of HSPCs, yet contains limited numbers of
cells in each unit. Despite these efforts, most attempts to use
expanded cord blood HSPCs in the clinic have been unsuc-
cessful due to the generation of insufﬁcient numbers of cells
with the appropriate phenotype and the ability to function in
vivo.
In many ex vivo culture systems, HSPCs are cultured as
a suspension cells and cultured in the presence of various
media additives that act to enhance cell proliferation while
reducing differentiation. An often-overlooked factorinﬂuencing fate decisions is the interaction of HSPCs with
a substrate. In the natural bone marrow microenvironment,
HSPCs maintain close contact with a complex network of
stromal cells and extracellular matrix, likely indicating that
cell-cell and cell-matrix interactions play an important role
in maintaining their stem cell phenotype. With the goal of
mimicking the bone marrow stem cell niche, Arteriocyte,
Inc. has developed a 3-D nanoﬁber-based cell culture
substrate. The functionalized nanoﬁber substrate is
designed to provide topographical and substrate-immobi-
lized biochemical cues that act in synergy with media
additives to enhance HSPC proliferation while minimizing
differentiation.
Here, we present our recent work towards developing
a closed, nanoﬁber-based platform for large-scale clinical
expansions of cord blood-derived CD34+ cells. We demon-
strate that our nanoﬁber substrate expands CD34+ cells from
cord an average of more than 150-fold in 10 day culture,
which is at least 2-fold higher than that obtained in standard
tissue culture plates. Additionally, we show an approxi-
mately 1.5-fold higher proliferation of colony forming cells
and a signiﬁcantly higher engraftment rate in NSG mice for
nanoﬁber-expanded cells compared to cells cultured in
tissue culture plates. Furthermore, we demonstrate that our
nanoﬁber scaffold maintains its HSPC growth promoting
characteristics after processing into a closed culture system
and offers signiﬁcant advantages over other culture plat-
forms typically used for HSPC expansions in the clinic
(culture bags and T-ﬂasks). Our data indicates that nanoﬁber
technology provides a robust ex vivo expansion of cord blood
HSPCs and, with further development, offers great potential
for clinical applications requiring large numbers of func-
tional cells.168
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Natural killer (NK) cells are a promising tool for cancer
therapy due to their ability to detect and eliminate cancer
cells. Using NK cells for therapeutic cell transfer in the
clinic requires high numbers of these cells. Therefore
a method for automated expansion of human NK cells is
developed.
Automation of NK cell expansion was done by use of the
CliniMACS Prodigy instrument, a novel technology for cell
processing in a clinical environment. Automated Ficoll
density gradient centrifugation was performed to remove
erythrocytes and granulocytes from buffy coat samples of
healthy donors and to obtain peripheral blood mononuclear
cells (PBMC). This automated method yielded a suitable
number of PBMC and a better depletion of granulocytes
compared to the manual PBMC preparation. PBMC were
cultivated with IL-2 and OKT-3 leading to an expansion of NK
cells, but also of NK like Tcells and Tcells. NK cell numbers up
to 5,1x108were reached with expansion factors of 54-208-
fold after three weeks. NK cell purities of 5-52% were
obtained.
Pure NK preparations are preferred with regard to
analysis of clinical outcome and to reduce the risk of graft
versus host disease possibly caused by contaminating T
cells.
